Is Erdafitinib effective in treating bladder cancer?

Erdafitinib (Erdafitinib) is the first targeted therapy drug approved for urothelial carcinoma patients. Erdafitinib is an effective and selective pan /span>FGFRTyrosine kinase inhibitor, erdafitinibIndicated for locally advanced or metastatic urothelial carcinoma with fibroblast growth factor receptor-2 (FGFR2) or FGFR3 gene alteration that has progressed during or after at least one cycle of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

APhase 2 clinical trial showed that patients treated with erdafitinib experienced an average of 5.5 months of progression-free survival span>(95%Confidence Interval[CI], 4.2-6.0months). Additionally, 40% (95% CI, 31-50%) of patients responded to erdafitinib treatment. Erdafitinibis available in tablet form and the current recommended daily dose is 8 mg, with the dose increased to 9 mg after 14 to 21 days of treatment, if tolerated. Erdafitinib binds to FGFR2 and FGFR3 receptors and inhibits FGF activity, leading to cell death.

Adverse reactions and laboratory abnormalities occurred in≥20% of patients: increased serum phosphate concentration, stomatitis, and fatigue. Chromium concentration, diarrhea, dry mouth, onycholysis, ALT and / or ASTIncreased concentration, increased alkaline phosphatase concentration, decreased serum sodium concentration, decreased appetite, decreased albumin concentration, dysgeusia, decreased hemoglobin concentration, dry skin, decreased serum magnesium concentration, dry eyes, hair loss, palms-soles Paresthesia syndrome(Hand-foot syndrome), constipation, decreased serum phosphate concentration, abdominal pain, increased serum calcium concentration, nausea, musculoskeletal pain. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0